Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P(1) Receptor Modulator in Clinical Trials

[Image: see text] Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within h...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ACS Med Chem Lett
Main Authors: Dhar, T. G. Murali, Xiao, Hai-Yun, Xie, Jenny, Lehman-McKeeman, Lois D., Wu, Dauh-Rurng, Dabros, Marta, Yang, Xiaoxia, Taylor, Tracy L., Zhou, Xia D., Heimrich, Elizabeth M., Thomas, Rochelle, McIntyre, Kim W., Warrack, Bethanne, Shi, Hong, Levesque, Paul C., Zhu, Jia L., Hennan, James, Balimane, Praveen, Yang, Zheng, Marino, Anthony M., Cornelius, Georgia, D’Arienzo, Celia J., Mathur, Arvind, Shen, Ding Ren, Cvijic, Mary Ellen, Salter-Cid, Luisa, Barrish, Joel C., Carter, Percy H., Dyckman, Alaric J.
Formato: Artigo
Idioma:Inglês
Publicado: American Chemical Society 2016
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4789672/
https://ncbi.nlm.nih.gov/pubmed/26985316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00448
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares